AKBA FY 2023 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$195M-33.5% YoY

Gross Profit

$120M61.9% margin

Operating Income

-$46M-23.8% margin

Net Income

-$52M-26.7% margin

EPS (Diluted)

$-0.28

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$242M

Total Liabilities

$272M

Stockholders' Equity

-$31M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$195M	$292M	-33.5%
Gross Profit	$120M	$270M	-55.4%
Operating Income	-$46M	-$81M	+42.7%
Net Income	-$52M	-$94M	+44.9%